Regulatory acceptance for OPC1 SC1 thoracic dose escalation Q1/2012
Regulatory acceptance for OPC1 SC1 cervical cohort Q1/2012
Declaration of IND Candidacy for GRN510 Q1/2012
PFS data in imetelstat Phase 2 in NSCLC Q2/2012
PFS data in imetelstat Phase 2 in Breast Cancer Q2/2012
ORR data in imetelstat Phase 2 in Multiple Myeloma Q2/2012
Hematologic response rate in imetelstat Phase 2 in ET Q2/2012
ORR data GRN1005 NSCLC brain mets Phase 2 Q4/2012
ORR data GRN1005 Breast Cancer brain mets Phase 2 Q4/2012.
2012 will be a very important year for Geron. With a new CEO who is a deal maker. The four phase 2 trials ending in Dec of 2012 and results will be reported then. I'm hoping for a $5 to $10 share price. I will be buying a few more shares on the dips and will sell a few shares and or sell some covered calls on the rips up.
Good luck in this rigged casino,
No comments:
Post a Comment